Connect with us

Hi, what are you looking for?

Editor's Pick

If You’d Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here’s How Much You’d Have Today

Eli Lilly’s (NYSE: LLY) broad portfolio of drugs has helped the company’s earnings climb over the years — and in recent times, two products in particular have supercharged growth. The big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss, and demand has been surpassing supply.

Pharmaceutical companies are generally viewed as safe investments — due to people needing their medications no matter what the economy is doing. This often results in a certain level of earnings stability. Lilly offers investors this investment profile, and thanks to its weight-loss drugs, it also brings the revenue growth you would expect from a more traditional growth stock. How has that translated into stock performance? Let’s find out.

Blockbuster drug Mounjaro

If you’d invested $10,000 in Eli Lilly stock five years ago, you would have $65,900 today. That’s a gain worthy of a top growth player. Lilly managed to draw the attention of a wide range of investors — from cautious to aggressive — as Mounjaro became a blockbuster drug. Now, the recently launched Zepbound is following in those footsteps.

In the most recent quarter, Mounjaro generated more than $1.8 billion in revenue, while Zepbound brought in about $517 million during its first full quarter of commercialization. The good news for shareholders and potential shareholders is that these gains are likely to continue. As mentioned, demand for these products is high, with Lilly and rival Novo Nordisk unable to keep up so far. (Both are ramping up production, though, which should help earnings climb further.)

According to Goldman Sachs Research, the weight loss drug market may reach $100 billion by the end of the decade. Meanwhile, Lilly has other weight-loss candidates in late-stage development, and if all goes well there, the company’s status as a weight-loss drug giant may continue for quite some time.

All this means that Eli Lilly stock could continue to reward investors over the long term.

This post appeared first on fool.com

You May Also Like

Investing

Newmont (NYSE: NEM) reported mixed financial results even as the price of gold approached its all-time high. In all, the company’s earnings per share...

Investing

Fisker (NYSE: FSR) stock price has been one of the best-performing electric vehicle (EV) stocks this week even as Tesla slumped. The shares jumped...

Investing

NatWest (LON: NWG) share price rose sharply, helped by the strong results from Barclays. The stock jumped to a high of 274.8p, which was...

Investing

The Fox Corporation (NASDAQ: FOX) stock price has been under pressure as investors come to terms with the abrupt firing of Tucker Carlson. The...




Disclaimer: Oldamericanbroker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the-company.


Copyright © 2024 Oldamericanbroker.com